Immunome Appoints Carol A. Schafer to Board of Directors
02 Januar 2024 - 2:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology
company focused on developing first-in-class and best-in-class
targeted cancer therapies, today announced the appointment of Carol
A. Schafer to its Board of Directors. Ms. Schafer has more than 25
years of experience in investment banking and equity capital
markets and has served as a corporate director for multiple public
companies.
“Carol’s financial expertise, strategic insight and
understanding of equity markets will greatly benefit Immunome as we
continue to expand and advance our pipeline of targeted oncology
therapeutics,” stated Clay B. Siegall, Ph.D., Chairman and Chief
Executive Officer of Immunome. “The Immunome leadership team will
draw on her experience as we work to develop best-in-class and
first-in-class treatments for cancer patients. We are pleased to
welcome her to the Board of Directors.”
“I am honored to join Immunome, and I am particularly impressed
by the company’s differentiated approaches to developing ADCs and
radioligand therapies and its platform for identifying
underexplored targets,” commented Carol Schafer. “I look forward to
collaborating with Immunome’s Board of Directors and management
team to advance its ambitious pipeline, realize its strategic goals
and maximize its strong financial position.”
Ms. Schafer currently serves as the Managing Partner of Hyphen
Advisors. Additionally, Ms. Schafer currently serves on the Board
of Directors of Insmed, Repare Therapeutics and Kura Oncology, and
previously served on the Board of Directors of Five Prime
Therapeutics and Idera Pharmaceuticals.
Prior to Hyphen Advisors, Ms. Schafer served as Vice Chair of
Wells Fargo Securities, where she led the healthcare equity capital
markets team and was responsible for originating and executing
equity and convertible financings. Prior to joining Wells Fargo
Securities, Ms. Schafer served as Vice President of Finance and
Business Development of Lexicon Pharmaceuticals. Previously, Ms.
Schafer served as Managing Director, Equity Capital Markets of
JPMorgan Chase working with companies in healthcare, retail,
consumer and chemical industries. Ms. Schafer earned her MBA from
New York University, and her BA in mathematics and computer science
from Boston College.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including radioligand therapies, ADCs, and
immunotherapies. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We may use words and
phrases such as “believes,” “plans,” “expects,” “will,” “assumes,”
“anticipates,” “looks forward to,” “works to,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions of the PSLRA.
These forward looking statements include, but are not limited to,
statements regarding Immunome’s expectation about the benefits that
a new director will have on Immunome, the expansion and advancement
of Immunome’s pipeline and Immunome’s approach and strategy related
to its pipeline; Immunome’s cash position; and other statements
regarding management’s intentions, plans, beliefs, expectations or
forecasts for the future. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. Such forward-looking statements are based on our
expectations and involve risks and uncertainties; consequently,
actual results may differ materially from those expressed or
implied in the statements due to a number of factors, including,
but not limited to, Immunome’s ability to grow and successfully
execute on its business plan, including advancing its current
pipeline and any additionally acquired assets into the clinic and
expanding its pipeline through its technology platforms,
proprietary toolbox and strategic transactions, if any; the ability
of Immunome to identify, conduct and complete IND-enabling studies;
changes in the applicable laws or regulations; the possibility that
Immunome may be adversely affected by other economic, business,
and/or competitive factors; the risk that regulatory approvals for
Immunome’s programs and product candidates are not obtained, are
delayed or are subject to unanticipated conditions that could
adversely affect it; Immunome’s ability to manage clinical trials
or studies; the risk that pre-clinical data may not be predictive
of clinical data; the complexity of numerous regulatory and legal
requirements that Immunome needs to comply with to operate its
business; the reliance on Immunome’s management and Board of
Directors; the prior experience and successes of the Immunome’s
management team and directors are not necessarily indicative of any
future success; uncertainties related to Immunome’s capital
requirements, expected cash runway and ability to raise additional
funds; the failure to obtain, adequately protect, maintain or
enforce Immunome’s intellectual property rights; and other risks
and uncertainties indicated from time to time described in
Immunome’s Annual Report on Form 10-K for the year ended December
31, 2022 filed with Securities and Exchange Commission (“SEC”) on
March 16, 2023, Immunome’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2023 filed with the SEC on November 9,
2023, and in Immunome’s other filings with the SEC. Immunome
cautions that the foregoing list of factors is not exclusive and
not to place undue reliance upon any forward-looking statements
which speak only as of the date made. Moreover, Immunome operates
in a very competitive and rapidly changing environment. New risks
emerge from time to time. Except as required by law, Immunome does
not undertake any obligation to update publicly any forward-looking
statements for any reason after the date of this press release to
conform these statements to actual results or to changes in their
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102053881/en/
Max Rosett Interim Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024